FCM
AQST icon

Flinton Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Flinton Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,604
Closed -$15K – 891
2019
Q2 		$15K Hold
3,604
– – ﹤0.01% 867
2019
Q1 		$25K Buy
+3,604
New +$25.2K ﹤0.01% 843

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Flinton Capital Management's AQST Position: Q3 2019 in Review

Flinton Capital Management sold out of Aquestive Therapeutics (AQST) in Q3 2019, closing a stake of 3,604 shares — an estimated $15K sold.

Flinton Capital Management first reported a position in AQST in Q1 2019 and held it in 2 quarters. The position peaked at $25K in Q1 2019. 35 funds tracked by Wall St. Rank hold AQST as of Q3 2019.

  • Flinton Capital Management reported no remaining Aquestive Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Flinton Capital Management sold 3,604 Aquestive Therapeutics shares in Q3 2019, an estimated $15K.
  • Flinton Capital Management first reported a position in Aquestive Therapeutics in Q1 2019 and held it in 2 quarters.
  • Flinton Capital Management's Aquestive Therapeutics position peaked at $25K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.